Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

FDA grants Rinvoq new indication for moderate to severe atopic dermatitis

By Brian Buntz | January 14, 2022

AbbVieFDA has approved Rinvoq (upadacitinib) from AbbVie (NYSE:ABBV) to treat moderate to severe atopic dermatitis in individuals at least 12 years old.

AbbVie anticipates 2025 risk-adjusted sales for Rinvoq to top $7.5 billion.

The most common type of eczema, atopic dermatitis, can be managed with various therapies, including corticosteroids, topical calcineurin inhibitors and immunosuppressants. Nevertheless, the disease can be persistent.

In 2017, FDA approved the first biologic for moderate to severe atopic dermatitis, Dupixent (dupilumab), from Regeneron Pharmaceuticals (NSDQ:REGN).

The new indication for the Janus kinase (JAK) inhibitor Rinvoq is constrained to individuals whose dermatitis has not responded to prior therapy. Alternatively, patients for whom such dermatitis therapies are not recommended are also eligible for Rinvoq.

Rinvoq

Image courtesy of AbbVie.

“This additional approval for Rinvoq provides a once-daily oral option that can significantly improve the debilitating itch and skin symptoms of atopic dermatitis,” said Dr. Thomas Hudson, senior vice president, research and development, chief scientific officer of AbbVie.

ABBV shares were up 1.36% to $135.34 in afternoon trading.

To win the new indication, AbbVie provided data from three Phase 3 studies focused on atopic dermatitis. The data indicated that Rinvoq recipients had a significant improvement in itching (pruritus) as early as the first week compared to placebo.

In early December, AbbVie updated the prescribing information for Rinvoq following discussions with the FDA to describe the increased risk in patients 50 and older with a heightened risk for cardiovascular disease.

FDA recommended the labeling updates for JAK inhibitors at large after announcing that it had observed an increased risk of serious adverse events in some patients taking the JAK inhibitor Xeljanz and Xeljanz XR (tofacitinib) from Pfizer (NYSE: PFE).

FDA first approved Rinvoq for moderate to severe rheumatoid arthritis in 2019. An indication for active psoriatic arthritis followed in December 2021.

 


Filed Under: clinical trials, Dermatology, Drug Discovery
Tagged With: AbbVie, atopic dermatitis, eczema, Rinvoq, upadacitinib
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50